Exenatide: research

Exenatide dosage

Typical reported dose: 5 mcg twice a day, then 10 mcg if needed

• Immediate release: 5 then 10 mcg twice daily: 5 mcg twice daily for 1 month, then 10 mcg twice daily if needed after 1 month twice daily, under the skin. Drug label. Studied in: Adults with type 2 diabetes. (source)
• Historical weekly depot: 2 mg: 2 mg once weekly once weekly, under the skin. Drug label. Studied in: Weekly exenatide diabetes label; BCise included adults and ages 10+. (source)
• Dose finding: 2.5 mcg twice daily: 2.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 5 mcg twice daily: 5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 7.5 mcg twice daily: 7.5 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)
• Dose finding: 10 mcg twice daily: 10 mcg twice daily; fixed dose. twice daily, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Exenatide side effects and risks

Reported side effects

• Nausea with immediate release: Pooled twice daily trials: 44% versus placebo 18%., moderate (source)
• Vomiting with immediate release: 13% versus placebo 4%., moderate (source)
• Diarrhea with immediate release: 13% versus placebo 6%., moderate (source)
• Weekly depot injection-site nodules: BCise pooled trials: 10.5%; nausea 8.2%., moderate. Persistent, painful, blistered or draining nodules need assessment. (source)
• Low blood sugar: With metformin plus sulfonylurea: 10 mcg 28%, 5 mcg 19%, placebo 13%., serious (source)
• Pancreatitis: Acute pancreatitis, including fatal or necrotizing cases, is reported; no reliable postmarketing rate., serious (source)
• Gallbladder disease: EXSCEL: 1.9% versus placebo 1.4%., serious (source)
• Kidney injury: Risk rises with dehydration or reduced kidney clearance; dialysis has been needed in reported cases., serious (source)
• Immune-related low platelets: Exenatide dependent antibodies can cause severe bleeding; reported postmarketing., serious (source)
• Serious injection-site injury: Abscesses, cellulitis and tissue death have been reported with weekly depot products., serious (source)
• Thyroid C-cell tumors with extended release: Weekly depot has a boxed rodent tumor warning; immediate release exenatide does not carry this boxed warning., serious (source)
• Severe allergic reaction: Anaphylaxis and angioedema have been reported; frequency unknown., serious (source)

Stop and get help if

• Severe, persistent belly pain, especially spreading to the back: Stop the drug and seek urgent care for possible pancreatitis.
• Face or throat swelling, trouble breathing, or collapse: Call emergency services now; do not take another dose.
• Confusion, seizure, fainting or low blood sugar that does not resolve: Get emergency care. If awake and able to swallow, use fast sugar while help is arranged.
• Repeated vomiting, inability to keep fluids down, or very little urine: Seek urgent assessment for dehydration and kidney injury.
• Upper-right belly pain with fever, yellow skin or pale stools: Seek urgent care for possible gallbladder or bile-duct disease.
• Sudden vision loss or a major new change in vision: Get urgent same-day eye or emergency assessment.
• Chest pain, marked breathlessness or fainting: Call emergency services now.
• New unusual bruising, pinpoint rash, bleeding or blood in stool: Stop exenatide and seek urgent care for possible immune low platelets.
• Painful, enlarging, blistered or draining depot injection site: Seek prompt care; serious injection-site injury sometimes needs surgery.

Who should avoid it

• pregnant: Weight loss is unsuitable; fetal-risk data are limited and animal findings raise concern.
• tryingToConceive: Review a stopping plan before conception; no safe conception interval was established in the extracted sources.
• breastfeeding: Human milk and infant-safety data are inadequate.
• under18: Some labeled diabetes or obesity uses include children; this is not a blanket pediatric label ban.
• mtcOrMen2: The MTC/MEN2 contraindication and boxed warning apply to the extended-release depot product. Immediate-release exenatide has its own product-specific contraindications. Weekly depot exenatide is contraindicated with MTC/MEN2. This caution applies across the profile; immediate release lacks this boxed warning.
• other: Do not re-expose after a serious allergic reaction to the drug or its ingredients.
• pancreatitisHistory: Past pancreatitis needs review; stop and urgently assess persistent severe abdominal pain.
• gallbladderDisease: Gallstones or previous gallbladder inflammation increase the need to assess new upper-abdominal pain.
• gastroparesis: Severe gastroparesis is a label reason to avoid use; these medicines further slow stomach emptying.
• eatingDisorderHistory: Listed as a reason to avoid it.
• kidneyDisease: Kidney function and hydration need review, especially with vomiting or diarrhea.
• liverDisease: Clinical experience in severe liver impairment is limited; review the specific product and other medicines.
• diabeticRetinopathy: Rapid glucose improvement can temporarily worsen diabetic eye disease; arrange appropriate eye follow-up.
• surgeryPlanned: Tell the anesthesia team. Delayed stomach emptying can leave food in the stomach despite fasting.
• diabetes: Review glucose monitoring and insulin or sulfonylurea doses. Do not rapidly stop insulin.
• other: Immediate release is not recommended with creatinine clearance <30 mL/min or end-stage kidney disease.
• other: Weekly BCise is not recommended below eGFR 45 mL/min/1.73 m².
• other: Prior exenatide-induced immune thrombocytopenia is a contraindication; re-exposure can trigger severe bleeding.

Interactions

• Insulin: Low blood sugar risk can rise. Insulin adjustment needs glucose readings; rapid withdrawal can cause ketoacidosis.
• Sulfonylureas and related insulin-releasing drugs: Low blood sugar can increase; a clinician may need to lower the companion drug dose.
• Another GLP-1 or GLP-1/GIP medicine: Avoid duplicate incretin therapy. Switching guidance stops the previous product rather than stacking both.
• DPP-4 inhibitors: Routine combination is not recommended because it adds little glucose benefit over GLP-1 therapy alone.
• Time-sensitive oral medicines: Slower stomach emptying can alter absorption timing; the effect is medicine-specific. Review critical oral drugs, especially with vomiting or poor intake.
• Warfarin: Raised INR, sometimes with bleeding, has been reported. Check INR frequently after starting or changing exenatide.
• Oral contraceptives and time-critical antibiotics: With immediate release, take at least 1 hour before exenatide when rapid absorption matters; check product-specific timing.

Product quality risks

• Online GLP-1 products can contain the wrong amount, a different drug or contamination. A seller’s purity claim does not establish sterile injectable quality.
• Three online semaglutide vials had 28.56–38.69% excess drug and endotoxin. Those samples were not this compound.
• No direct online exenatide assay survey was found. A plain powder cannot reproduce the weekly or monthly release system.

How Exenatide works

It copies a gut hormone that helps you feel full. It increases insulin release when blood sugar is high, lowers glucagon, and slows food leaving the stomach.

• GLP-1 receptor: Increases glucose-dependent insulin release, lowers glucagon and slows stomach emptying.

Half-life: Immediate-release exenatide: about 2.4 hours. Weekly depot release persists much longer.